Sunoo Kang
MCPHS - Boston, PharmD Candidate 2026
Email
Email
LinkedIn
LinkedIn
[Google Form] Midyear Poster Feedback / Questions
[Google Form] Midyear Poster Feedback / Questions
Hi! Connect with me on LinkedIn 🤓
Hi! Connect with me on LinkedIn 🤓
Key Studies from the Poster
SUMMIT (N Engl J Med. 2025)
SUMMIT (N Engl J Med. 2025)
STEP-HFpEF (N Engl J Med. 2023)
STEP-HFpEF (N Engl J Med. 2023)
STEP-HFpEF DM (N Engl J Med. 2024)
STEP-HFpEF DM (N Engl J Med. 2024)
Among patients with obesity-related heart failure with preserved ejection fraction and type 2 diabetes, semaglutide led to larger reductions in heart failure-related symptoms and physical limitations and greater weight loss than placebo at 1 year. (Funded by Novo Nordisk; STEP-HFpEF DM ClinicalTrial …
Pre-specified pooled analysis of STEP-HFpEF/DM (Lancet. 2024)
Pre-specified pooled analysis of STEP-HFpEF/DM (Lancet. 2024)
Post-hoc pooled analysis of SELECT/FLOW/STEP (Lancet. 2024)
Post-hoc pooled analysis of SELECT/FLOW/STEP (Lancet. 2024)
View on mobile
![[Google Form] Midyear Poster Feedback / Questions](https://waps.l3s.uni-hannover.de/live/im_/https://ugc.production.linktr.ee/4c7e64d2-a911-4cad-a502-cffa867ae7d3_VAC1sfMK-K3--wsYpwuy9F4twCesYCCqdzgpKKpWRjfPc-Qv6A22fAG779PY9Mh1f6EzuTWHRLmFXA8-w1200-h630-p.png?io=true&size=thumbnail-stack_v1_0)